During the Microbiome Connect Europe conference, held early in July in Amsterdam, Microbiome Post sat down with Pilar Manrique Ronquillo, Research Scientist at Microviable Therapeuthics, to learn more about the donor-based microbiome therapeutic products research and development.
Microviable develops novel biological drugs and personalized therapies to address unmet challenges in human diseases providing innovative solutions based on the microbiota. Microviable is a preclinical stage company developing novel biological drugs, based on commensal bacteria, targeting infectious diseases. Our lead candidate, MVT-201, is an orally administered capsule generated under cGMP conditions that represents the complete microbiota ecosystem and will enter clinical trials in Q4 2023.
